MaRS and Beyond: How Toronto Engineered a Biomedical Growth Engine

Something quietly extraordinary has been happening in the heart of downtown Toronto. Within one of the most compact geographies of scientific activity in North America, a high-functioning biomedical innovation engine has been built. This engine, powered by world-class research output, startup formation, and translational medicine, isn’t operating in a vacuum. It was engineered.

While Boston and the Bay Area dominate global biotech headlines, Toronto has opted for a less explosive but structurally solid approach: proximity, infrastructure, and strategic government coordination. The result is an ecosystem that continuously produces high-potential companies and globally relevant therapies. However, Toronto still grapples with a challenge: how to keep what it grows. This deep dive goes beyond introductory overviews to examine the economic geography, institutional logic, commercialisation strategies, and structural frictions of the Toronto biomedical innovation model.

Readers interested in how ecosystems can be constructed—not merely emerge—will find this account of Toronto essential. It complements our other research into ecosystem engineering strategies, including Osaka’s translational pivot, and Fukuoka’s infrastructure playbook.

The Urban Blueprint: Agglomeration as Innovation Architecture

Toronto’s Discovery District occupies less than one square mile but packs in more than nine major hospitals, 30+ research institutions, and the globally ranked University of Toronto (U of T). This hyper-dense cluster is urban planning as a strategic asset. The ecosystem’s architecture is based on the concept of super-agglomeration, where the friction of physical distance is minimised, enabling faster translation from lab to clinic to capital.

Everything is literally connected. The MaRS Discovery District is physically embedded in Toronto’s PATH underground system and subway, linking labs, hospital wards, and financial institutions within walking distance. This urban connectivity functions like a circuit board: power (capital), data (clinical trials), and design (research) all flow efficiently within an engineered layout. The Triple Helix model, with government, academia, and industry working in tandem, is evident in policy and street-level experience.

Regenerative Medicine and the Rise of CCRM: A Deeper Dive into Industrialization

Comparative Advantage: CCRM vs. T-CiRA (Kyoto)

Compared to Japan’s T-CiRA, which operates with stable but inward-looking block funding from Takeda, Toronto’s CCRM relies on a mix of grants, service revenue, and venture returns. While this model is more volatile, it allows greater ecosystem diversity and international VC access. The launch of OmniaBio, a commercial-scale CDMO subsidiary, represents CCRM’s next move. They are anchoring IP as they provide physical production capacity in Canada.

While MaRS built horizontal capability, one standout vertical success is the Centre for Commercialization of Regenerative Medicine (CCRM). Founded in the early 2010s, around the same time as Kyoto University’s CiRA, CCRM was designed to take regenerative medicine from lab curiosity to market-ready platform.

Unlike typical research consortia, CCRM functions as a hybrid: part venture creation studio, part seed investor, and part CDMO. This integrated structure allows early RM startups to access infrastructure and capital without losing momentum in their most vulnerable stage.

Notable portfolio companies:

• ExCellThera: A cell expansion platform company that partnered with multiple hospitals for hematologic trials.

• Notch Therapeutics – building allogeneic, iPSC-derived T-cell therapies

• AVROBIO – a gene therapy company that went public on NASDAQ before being acquired by Tectonic in 2024

The Cytiva Partnership

In a rare move for public-private collaboration, CCRM partnered with Cytiva (formerly GE Life Sciences) to create the Centre for Advanced Therapeutic Cell Technologies (CATCT). Backed by CAD 40M in combined funding from Cytiva and the Canadian government, CATCT allows early-stage ventures to develop GMP-grade manufacturing protocols without building internal facilities. It’s a critical capability as, in cell therapy, “the process is the product”.

Metrics of Performance: From Papers to Patents to Public Markets

Canada’s scale, on paper, looks modest: around 200,000 researchers in a country of 40 million. Yet output tells another story. Canada consistently ranks among the global top 10 for:

• Scientific publications in high-impact journals

• Patent families filed internationally

• Biotechnology VC investment (approx. CAD 10 billion annually)

Toronto alone ranks 22nd in the Global Startup Ecosystem Index (2024) — a respectable position considering its proximity to Boston, the world’s most competitive cluster. The ecosystem’s inclusive policy toward immigrant entrepreneurs and international students further expands its talent pool, increasing retention and boosting startup formation.

This Toronto’s data-driven biomedical innovation model is one where performance is tracked not only by funding rounds or acquisitions, but by intellectual throughput and industrial absorption. These two metrics usually signal long-term value over short-term hype.

MaRS and Beyond: How Toronto Engineered a Biomedical Growth Engine.

From Cohesion to Friction: TAHSN, Talent, and the Retention Problem

The Toronto Academic Health Science Network (TAHSN) is a major contributor of IP, talent, and translational research. Its unique “joint appointment” system ensures that clinician-scientists work fluidly across hospitals and universities, enhancing clinical validation and cross-training.

Yet, beneath this academic cohesion lies real friction:

• IP Fragmentation: U of T, UHN, and other institutions have differing IP policies. Negotiating inter-institutional agreements is slow and often delays company formation.

• Data Silos: While the region’s single-payer health system should enable AI-driven clinical insights, lack of unified EHR systems and varying interpretations of PHIPA law make data aggregation extremely difficult.

The Retention Paradox: Capital, Salaries, and Procurement Gaps

Toronto succeeds in starting companies but struggles to scale and retain them. At the Seed and Series A levels, funds like MaRS IAF and Amplitude Ventures are active. But when companies need $100M+ to enter Phase 2/3 trials, U.S. capital steps in. This often means incorporation in Delaware and relocation of executives to Boston.

Why some Canadians leave Canada

• Salary Chasm: Executives can double their pay by moving south, while facing lower tax rates and equal or better cost of living.

• Procurement Failure: Even when Ontario companies develop FDA-approved products, local hospitals often delay adoption due to budget constraints and risk aversion.

Two policy attempts, the Building Ontario Business Initiative (BOBI) and the Health Innovation Pathway (HIP) are underway, but cultural resistance within the public healthcare system remains significant.

Strategic Outlook: Anchor, Not Accelerate

Toronto’s model is now pivoting. The goal is no longer just more startups, but anchoring critical industrial capabilities like GMP manufacturing, late-stage capital, and executive leadership. Investments in OmniaBio, shifts in pension fund policy, and reforms in local procurement hint at a strategy to build retention infrastructure.

The Toronto biomedical innovation model is an architecture in evolution. Other regions considering how to transition from discovery to durability would do well to study its mechanisms and its ongoing gaps.

Here’s a similar deepdive, but into Japan!

We have been supporting cross-border commercialization in Japan for almost 20 years and are eager to explore your needs and expectations in biomedical innovation strategies. You are warmly welcome to book a meeting directly here https://www.calendly.com/biosector or send an email to info@biosector.jp